Despite the results of the NSABP B-47 trial showed that trastuzumab does not provide any survival benefits for patients with HER2-low expression breast cancer [7], recent developments in antibody-drug conjugates (ADCs) have demonstrated positive outcomes in treating this type of cancer, bringing new possibilities for patients [8]. Here, ERBB2 is linked to breast carcinoma.